0.00
price down icon100.00%   -0.0949
after-market Dopo l'orario di chiusura: .09 0.09 +
loading

AIM ImmunoTech Inc Borsa (AIM) Ultime notizie

pulisher
May 16, 2025

AIM ImmunoTech Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 08, 2025

AIM ImmunoTech Announces the Presentation of Ampligen - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - Stock Titan

May 08, 2025
pulisher
May 03, 2025

AIM ImmunoTech Announces Launch of CEO Corner Platform - Investegate

May 03, 2025
pulisher
May 02, 2025

AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 - ACCESS Newswire

May 02, 2025
pulisher
May 01, 2025

AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference - ACCESS Newswire

May 01, 2025
pulisher
Apr 29, 2025

AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 28, 2025

AIM ImmunoTech files to sell units, no amount given - MSN

Apr 28, 2025
pulisher
Apr 27, 2025

AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 15, 2025

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail

Apr 15, 2025
pulisher
Apr 13, 2025

AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com

Apr 13, 2025
pulisher
Apr 12, 2025

AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN

Apr 12, 2025
pulisher
Apr 10, 2025

AIM ImmunoTech appoints Chemerow as an Independent Director - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech Changes Markets: Key Details of AIMI Ticker Switch and Special Meeting - Stock Titan

Apr 07, 2025
pulisher
Apr 05, 2025

Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com Australia

Apr 05, 2025
pulisher
Apr 05, 2025

Aim Immunotech’s COO Peter Rodino III acquires shares for $43 By Investing.com - Investing.com India

Apr 05, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech faces NYSE American delisting over low stock price By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech announces NYSE American notice of delisting and appeal - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - marketscreener.com

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire

Apr 04, 2025
pulisher
Apr 04, 2025

Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 03, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada

Apr 02, 2025
pulisher
Apr 01, 2025

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 31, 2025
pulisher
Mar 28, 2025

Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings Preview For AIM ImmunoTech - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Inc. (AIM) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan

Mar 27, 2025
pulisher
Mar 19, 2025

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World

Mar 18, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq

Mar 11, 2025
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Capitalizzazione:     |  Volume (24 ore):